Malaghan Institute of Medical Research, Wellington, New Zealand 1 Center for Neurologic Diseases, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, USA 2 Laboratory of Transplantation Immunology and Nephrology, Department of Research, University Hospital Basel, CH-4031 Basel, Switzerland
Correspondence to: B. T. Bäckström; Email: tbackstrom{at}malaghan.org.nz
Transmitting editor: S. Akira
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Keywords: antigen signaling, structurefunction, T cell receptor
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
T cells express a TCR consisting of clonotypic ß- or
-heterodimers associated with the CD3-
and
chain homodimers. The
ß and
TCRs show sequence homology but may still have different structural properties. For example, a CD3-
epitope detected with the mAb WT31 in the
ß TCR complex is masked in T cells expressing the
TCR (1,2). In addition, unlike the
ß TCR, the
TCR is predominantly expressed without CD3-
(3), and CD3-
deficient mice lack
ß- but not
-expressing T cells (4). These examples indicate that the
TCR can be expressed at the cell surface in the absence of the CD3-
chain, and that the structural requirement for cell surface expression may differ between
ß- and
-expressing T-cell subsets.
While the variable region of the TCR-ß and -
chains is responsible for antigen recognition, intracellular immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3-
and
chains are essential for TCR signaling. However, it is still not certain which domains in the constant regions of the TCR-
ß chains are involved in signal transmission, or how the TCR links antigen recognition to ITAM phosphorylation and downstream signaling. Interestingly, structural differences between
ß and
T cells impact on receptor signaling and
ß/
lineage determination (5). Some evidence suggests that
T cells may induce different downstream signaling events to
ß T cells. For example,
-expressing T cells do not depend on CD4 or CD8 for activation, and have different requirements for PLC-
1 and protein tyrosine kinase activation of the guanine nucleotide-exchange factor Vav (69).
To better understand the signaling capabilities of the TCR, it is important to study domains in the TCR-ß that are not directly involved in antigen recognition, but may influence the association with the CD3-
and
chains. To do this, we took advantage of the similarities and differences between the
ß and
TCR constant regions by making chimeric
and ß chains containing different lengths of TCR-
and
chain amino acids, respectively. By studying some of these chimeric TCR chains, we have previously identified a motif in the connecting peptide domain of the TCR-
chain (
CPM), and shown that it is involved in antigen-signaling and association with the CD3-
chain (10,11). Interestingly, disruption of
CPM affects positive but not negative selection of thymocytes (10,11), indicating that the different domains of the TCR carry out specialized functions. Furthermore, TCR-ß connecting peptide domain is also involved in signaling, since hybridoma cells possessing mutations within this domain are unresponsive to superantigen stimulation. In spite of the pronounced signaling defect found, the interactions of the chimeric TCR-ß chain with the CD3-
and
chains are preserved (11,12).
The T- and B-cell receptors contain a conserved antigen receptor transmembrane (CART) motif, suggesting an important role for this domain in antigen receptor assembly and function (13). To study the role of the TCR-ß chain transmembrane domain on TCR structure and function, we utilized a previously generated chimeric TCR-ß chain (ßIII) which contains TCR- amino acids downstream of the conserved transmembrane Y145 residue (11). We demonstrate that T hybridoma and transgenic T cells expressing the chimeric TCR-ßIII chain show super-signaling properties upon stimulation through the TCR with antigen, but not upon CD3 cross-linking. As the association with the CD3-
and
chains is intact, the super-signaling TCR-ßIII complex appears to have normal structure but altered function.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Generation of DNA constructs and myelin oligodendrocyte glycoprotein (MOG) peptide 3555-specific transgenic mice
The V2.1 and Vß8.1 TCR cDNAs were isolated from the T-cell hybridoma 3BBM74 as previously described (11). They confer reactivity to the I-Abm12 alloantigen and the SEB superantigen. Cloning of the MOG3555-specific T-cell receptor 2D2 (V
3.2 and Vß11) has previously been described (16). For construction of wild-type and chimeric TCR tg mice, the VJ segments of the 2D2
and VDJ of the ß chain were amplified by PCR using 2D2 cDNA as template and the following primers: V
-5': GATCGAATTCGTCGACATGCTCCTGGCGCTCC, V
-3': GT TCTGGGTTCTGGATGTTGGGCTTGATAGATAACTTG, Vß-5': GATCGAATTCGTCGACATGGCCCCCAGGCTCCTT, Vß-3': GTCACATTTCTCAGATCCTCTACAACTGTGAGTCTGG. The constant
and ß chains were amplified by PCR from LXSN-V
2.1, LXSP-Vß8.1 and LXSP-Vß8.1-ßIII (11) as templates for the constant
, constant ß and constant ßIII (chimeric ß/
) chains respectively. The following primers were used: C
-5': CAAGTTATCTATCAAGCCCAACATCCAGAACCCAGAAC, Cß-5': CCAGACTCACAGTTGTAGAGGATCTGAGAAATGT GAC, LXSN/P-3': GGGCGGGACTATGGTT. The variable and constant chain PCR products were sewn together in a PCR using either the V
or Vß upstream primer with LXSN/P-3' and the resulting PCR products were TA cloned in pCR2.1 (Invitrogen, Carlsbad, CA) in accordance with the manufacturers recommendations. The cloned PCR products were sequenced, excised from the cloning vector with SalI/BamHI, and cloned into the SalI/BamHI sites of the pHSE3' vector (17). For construction of transgenic mice, the DNA fragment coding for the TCR chains were excised from pHSE3' with XhoI, gel purified, and microinjected into C57BL/6J oocytes as previously described (16).
Retroviral infection of 58hCD4 cells
The generation of virus-containing supernatants by transfection of Phoenix cells and retroviral infection of hybridoma cells was done as previously described (11). Briefly, 2.5 x 105 Phoenix cells/well were seeded in 6-well plates and transfected with 2 µg of retroviral vector the day after using 6 µl of Fugene6 (Roche Diagnostics, Auckland, NZ) according to the manufacturers recommendations. The supernatant, 2 ml, containing the retroviral particles was supplemented with 10 µg/ml of polybrene (Sigma, Global Science, Auckland, New Zealand) and added to 2.5 x 105 hybridoma cells. For selection of positive cells, LXSP-infected cells were added 3 µg/ml of Puromycin (Sigma), and LXSN infected cells 1 mg/ml G418 (Merck, Palmerston North, New Zealand). The selective drug was added to the cell culture 24 h after infection. Bulk-infected cells were sorted by flow cytometry for equal expression of the TCRs and human CD4 chains and then used in indicated experiments.
Electroporation of 58ß T hybridoma cells
For expression of 2D2 TCR and murine CD4 in 58ß T hybridoma cells, pcDNA3/neo (for G418 selection) and pcDNA/L3T4 (murine CD4) were linearized with PvuI and ScaI respectively, while pHSE3'/2D2
wt, pHSE3'/2D2ßwt and pHSE3'/2D2ßIII were linearized with XhoI. The linearized DNA was precipitated and dissolved in PBS. For electroporation, 5 x 106 58
ß T hybridoma cells were electroporated in 200 µl PBS containing 2 µg pcDNA3/neo, 4 µg pcDNA3/L3T4, 10 µg pHSE3'/2D2
wt and 10 µg of either pHSE3'/2D2ßWT or pHSE3'/2D2ßIII at 960 µF and 0.25 kV using a Bio-Rad Gene Pulser (Bio-Rad, San Diego, CA). Surviving cells were cultured for 24 h in complete medium after which they were seeded at 5 x 103 cells/well in 96-well plates in complete medium containing 1 mg/ml of G418. Surviving clones were screened for V
3.2, Vß11 and mCD4 expression using flow cytometry. One 2D2 wt and one 2D2 ßIII expressing clone was found to respond to MOG3555 and therefore selected for this study. These clones were stained with anti CD4/PE and anti TCR-ß/FITC and sorted for equal expression of TCR and mCD4, using a FACSVantage Flow Cytometry System (Becton Dickinson).
Antibodies, peptides and superantigen
The MOG3555 peptide was synthesized by Mimotopes (Clayton, Australia) and was more than 90% pure, confirmed by HPLC. The peptide sequence for mouse MOG3555 is MEVGWYRSPFSRVVHLYRNGK. SEB was purchased from Toxin Technology, Inc. (Sarasota, FL). The antibodies B20.1 (anti V2.1), RR3-16 (anti V
3.2), H28710 (anti TCR-
constant region), F23.1 (anti Vß8), RR3-15 (anti Vß11), H57597 (anti TCR-ß constant region), 1452c11 (anti CD3-
), H129.19 (anti mouse CD4), RPA-T4 (anti human CD4), or H146968A (anti
) were used. All mAbs were either purchased from BD PharMingen (San Diego, CA) or purified from culture supernatants. Goat anti-rabbit-HRP (Southern Biotechnology Associates, AL) and goat anti-Armenian hamster-HRP (Jackson ImmunoResearch Laboratories, Inc.) were used as secondary antibodies for their respective primary antibodies.
Hybridoma stimulation assay
For hybridoma stimulation assays, 5 x 104/well hybridoma cells were seeded in 96-well plates. Hybridoma cells were stimulation with indicated concentration of the MOG3555 peptide and 5 x 105/well irradiated (2000 Rad) C57BL/6J splenocytes. For stimulation with SEB, 2 x 104/well LG-2 cells and SEB at indicated concentrations were added. The cultures were incubated for 24 h, after which culture supernatants were harvested. To quantify the concentration of IL-2 in the culture supernatants, 5 x 103 HT-2 cells in 100 µl were cultured with 100 µl culture supernatant for 24 h and 0.5 µCi/ml of [3H]thymidine added for the final 6 h of incubation. The amount of IL-2 was expressed as the HT-2 stimulation index (SI) (proliferation of HT-2 cells with culture supernatant from stimulated cells/proliferation of HT-2 cells with culture supernatant from unstimulated cells). Alternatively, recombinant IL-2 was added as a standard to calculate total units of IL-2.
T-cell stimulation and proliferation assay
Splenocytes, 4 x 106 cells/well in 24-well plates, from wild-type and ßIII 2D2 mice were stimulated with 10 µg/ml MOG3555, and IL-2 (50 U/ml) added on day 2, 5 and 8. On day 9, cultures were washed twice and 3 x 104 T cells/96-well mixed with 5 x 105 irradiated splenocytes and antigen. The T-cell cultures were incubated for 72 h and 0.5 µCi/ml of [3H]thymidine added for the final 9 h of incubation.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
Super-signaling MOG3555-specific TCR transgenic T cells
In order to evaluate the super-signaling chimeric ßIII TCR in a more physiological system, we generated TCR transgenic mice expressing either the ßwt or chimeric ßIII chain together with the wild-type 2D2 V3.2 chain. We stimulated splenocytes from 2D2 TCR transgenic mice with MOG3555 and then expanded the T cells with IL-2 for 9 days. Naive splenocytes from both 2D2
wt/ßwt and
wt/ßIII mice, and cells cultured for 9 days with IL-2, expressed similar levels of the V
3.2, Vß11, CD3
and CD4 molecules at the cell surface (Fig. 4A, and data not shown). These short-term T-cell lines were then tested for proliferative responses to antigen and superantigen stimulation. We found that the T cells expressing the
wt/ßIII TCR proliferated better in response to MOG3555 (Fig. 4B) and SEB (Fig. 4C), compared to T cells carrying the
wt/ßwt TCR. These results indicate that the chimeric ßIII chain renders T cells hyper-responsive to antigenic signals delivered through the TCR-
ß chains, and that the phenotype is not due to increased TCR expression.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Here, we further analyze the role of the chimeric TCR-ßIII chain, which contains TCR- amino acids downstream of the conserved transmembrane Y145 residue. Introducing the chimeric ßIII TCR together with the wild-type TCR-
chain renders hybridoma cells and transgenic T cells
10-fold more sensitive to antigen stimulation (MOG3555 and SEB), but not to stimulation by anti-CD3 cross-linking. We have previously shown that the
wt/ßIII TCR associates with the CD3-
and
chains at the cell surface, using biotinylation and immunoprecipitation techniques [(11) and data not shown]. Thus, the super-signaling phenotype of the chimeric ßIII TCR is not due to a change in the assembly of the TCR with CD3-
or
chains or higher surface expression of the chimeric TCR (Figs 3A and 4A). The phenotype of the chimeric ßIII chain is most likely mediated by changes in the transmembrane domain of the TCR-ß chain, since we have previously demonstrated that the short intracellular domain of the TCR-ß chain is dispensable for TCR signaling (18).
The transmembrane domain of the TCR-ß chain has previously been implicated to be involved in TCR signaling. By introducing point mutations, it has been revealed that TCR-ß transmembrane residues contribute towards both T-cell activation and apoptosis (20,21). Mutating one or both of the two conserved tyrosines (Y145 and/or Y155) to phenylalanine in the transmembrane region of the ß chain causes a marked reduction in antigen responsiveness in mouse hybridoma cells. Likewise, mutating the conserved transmembrane C-terminal tyrosine (Y155) to leucine in Jurkat cells affects the association of the chain with the TCR complex. Interestingly, these Jurkat cells show normal IL-2 secretion, but reduced apoptosis and FasL upregulation in response to anti-CD3 stimulation (2224). However, the super-signaling phenotype of the chimeric TCR-ßIII might be due to a different mechanism, since both the TCR-ß and TCR-
chains possess the transmembrane Y145 and Y155 residues (11). In addition, a chimeric TCR-ß chain, ßII, containing TCR-
-derived amino acids from the conserved transmembrane residue K151 and downstream paired with the wild-type TCR-
chain does not show any super-signaling properties [(11) and data not shown]. The only difference between these two chimeric TCR-ß chains is between positions 146150 in the transmembrane domain, where ßII encodes the TCR-ß-derived amino acids EILLG, and ßIII the TCR-
derived amino acids LLLLL. Thus, the super-signaling phenotype is most likely attributed to the replacement of the conserved E146 and G150 amino acids in the TCR-ß chain to L146 and L150.
Transmembrane domains often possess an -helix structure with every three/four amino acids ending up in the same vertical plane (13). The spacing between E146 and G150 is four amino acids and they are therefore likely to face the same side. Bäckström et al. (11) have previously reported that, whereas single point mutations within the
CPM do not affect TCR signaling, substituting three amino acid residues within the same motif renders the resulting TCR non-functional. This indicates that small changes are tolerated without affecting the function of the TCR. It is possible that the E146 and G150 residues of the TCR-ß chain are part of an important TCR-ß chain transmembrane motif and interact directly with the CD3/
complex and that the interface is made up by a number of additional amino acids, all of which contribute to the interaction. Substituting E146 and G150 with the corresponding TCR-
leucine residues in the ßIII chimera could therefore be structurally tolerated, but with altered TCR signaling. On the other hand, the corresponding TCR-
leucine residues, in conjunction with residues found further downstream, might be part of an important motif in the
TCR complex which makes the ßIII chain interact more efficiently in comparison to ßII (or the wild-type TCR-ß chain) and thus renders this TCR hyper-active. Another possibility is that the TCR-
chain leucine residues are less efficient, in comparison to the wild-type TCR-ß chain, in interacting with a transmembrane-resident molecule involved in TCR-induced inhibition, and therefore cells expressing the ßIII TCR show a fictional hyper- proliferative response.
In summary, the ßIII chain generates a TCR with an apparent super-signaling phenotype which is not limited to one TCR, since both alloantigen (I-Abm12) and autoantigen-specific (MOG3555) TCRs expressing this chimeric ßIII chain are hyper-responsive upon antigen stimulation (Figs 2 and 3). We are currently in the process of investigating how the chimeric ßIII chain affects downstream signaling pathways. In addition, the super-signaling MOG3555-specific C57BL/6J TCR transgenic mice may represent a novel model for studying how changes in TCR signaling affect the development of an autoimmune disorder, using the experimental autoimmune encephalomyelitis model for human multiple sclerosis.
![]() |
Acknowledgements |
---|
![]() |
Abbreviations |
---|
CPMconnecting peptide motif
ITAMimmunoreceptor tyrosine-based activation motif
MOGmyelin oligodendrocyte glycoprotein
SEBStaphylococcal enterotoxin B
TCRT-cell receptor
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|